Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?

On Thursday, Aadi Bioscience, Inc. AADI entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd.Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging Hangzhou DAC’s CPT113 linker payload technology.Also Read: Cancer ...